Participants 68 118 6
patients with established coronary artery disease.
Participants 409 554 4
patients with coronary artery disease with sulfasalazine, an inhibitor of NFκB, and placebo in a randomized, double-blind, crossover study desig
Participants 704 777 6
 53 patients enrolled in the crossover study, 32 (age 60 ± 10, 22% femal
